Shots: The sBLA is based on P-II KEYNOTE-158 study assessing Keytruda (200mg, q3w) in patients with solid tumors. The study also supported Merck’s 2017 FDA approval for Keytruda as the […]readmore
Tags : Biomarker
Shots: ADC Therapeutics’s to utilize Freenome’s multiomics platform to identify biomarkers correlating with clinical response to ADC’s ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma […]readmore